Madrigal Pharmaceuticals 10K 2013 Annual report | MDGL Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abiraterone, Abraxane, adaptive, advocacy, age, Alan, ambiguity, Anderson, appointed, arrhythmia, Arthur, ATR, Bansal, bar, Bayesian, Belgium, bendamustine, Bernitz, Berry, breadth, Breakthrough, brentuximab, brochure, Buck, Burnett, cardiac, Carol, cease, Celgene, Celldex, Centre, Cerulean, CFR, Chairman, Chase, checkpoint, chemosensitive, choice, CI, cleavable, Cobraxane, College, compromised, confound, conjugate, consortium, constrained, Cox, creation, DA, Dana, daunorubicin, de, Deactivate, deadly, degredation, Denmark, difficulty, Diller, disordered, divided, door, driven, driver, Eastern, EBCC, ECG, eLDH, emtansine, Endocyte, Enzon, epigenetic, ER, Esserman, explanation, Farber, fashion, feasibility, Figure, Fox, Francisco, Frank, friedman, Genentech, graduate, Haematological, HDC, Helen, hematopoietic, heterogeneity, higher, home, imaging, immature, Immunogen, infrequent, Innsbruck, invented, irreversible, joined, Kadcyla, Laura, leaving, Leicester, lenalidomide, leukemic, linker, London, long, lt, mainstay, McMahon, MD, MDS, mechanistic, medium, MEK, Merrimack, Mersana, micromolar, minumum, mTOR, multicenter, multivariate, myelodysplastic, NCRI, neoplasm, nerve, NYC, older, Opaxio, opposed, pace, panobinostat, paul, payload, PDFGR, peripheral, pharmacodynamic, Philadelphia, pilot, pomalidomide, poor, poster, predefined, preferential, preferentially, principle, proceeding, Professor, Programme, proof, purely, QLHC, QTc, QuantumLeap, radiolabeled, RAF, reaction, Remarkably, remission, resigned, Sanjay, science, Seattle, Serial, session, sheath, shortly, Simon, skilled, skin, sorafenib, SPA, sparing, sponsorship, Steven, stronger, Strongly, Subpart, subset, subtype, sunitinib, supposed, surface, surgery, survivin, suspected, syndrome, team, temozolomide, thirty, thrombocytopenia, topotecan, traditionally, translocation, trap, triplet, turn, UCSF, umbrella, unadjusted, unconjugated, univariate, upregulated, UT, vedotin, VEGFR, vi, vintafolide, Viventia, vorinostat, vulnerable, WCLC, weak, weekly, Western, younger, Zealand, zone

Removed: affinity, ASH, Avastin, awarded, Bo, calculated, Canada, Chen, committed, contractually, creative, crolibulin, durable, electrophysiology, elucidation, endothelial, EpiCept, Erbitux, escalation, evaluable, expression, flexibility, flow, frequently, GCP, gene, Gleevec, globally, guideline, Hematology, Hospital, interference, intervention, joint, judge, Keizo, Koya, Lan, linked, Margaret, modeled, Nexavar, nonstatutory, occurrence, origination, orin, oxigene, plinabulin, potently, purification, radiotherapy, regionally, reliable, RNA, shrinkage, silico, Sutent, synergy, synthetic, Tarceva, throughput, tolerability, Toronto, traditional, tyrosine, underwritten, vascular, vasculature, whichever, York

Madrigal Pharmaceuticals (MDGL) 10-K2013 FY Annual report

Content analysis